Group 4H: Triple Negative Breast Cancer; Predictive Biomarkers; Novel Targets & Treatments

Thursday, Dec 15
10:00 am – 11:30 am Eastern Time (US/New York)

Poster #P5-06-06

TROP2 and HER2 expression by liquid biopsy in women with mTNBC

Poster #PD11-09:

Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

Mentor: Barbara Bigelow

Barbara is a licensed psychologist and worked most of her life as a high school psychologist. Barbara has had breast cancer for 20 years, the last 7 as metastatic. A vocal advocate for patient research, she herself was in a clinical trial for immunotherapy that landed her in the hospital for 2 months. Along the way she has also survived lung cancer and melanoma. Today she is the Vice President of Metavivor, committed to raising money to fund metastatic breast cancer research. She also blogs about her experiences using humor to inspire hope for others at The Cancer Chronicles.

You may recognize her from the registration desk at the DC Stampede, the 2018 Elements Campaign with her daughter Bridget for #thisismnc, the Count Me In video for the MBC Project, live streaming from LBBC or walking the runway in New York Fashion Week 2019 (#notjustone)

Twitter: @tbigelow1953

Scientist: Julia Foldi, M.D., Ph.D.

Julia trained as a researcher in immunology prior to switching careers slightly to become a physician. She completed her Oncology training at Yale University, where she first interacted with patient advocates while developing her first clinical trial protocol. Julia recently moved to the University of Pittsburgh to begin her first faculty position as a Breast Medical Oncologist. In her new role as a clinical and translational breast cancer researcher, she is hoping to continue developing her relationships with local and national patient advocacy organizations and help connect other physician and scientists with patient advocates. She hopes to use these connections in her practice and research to develop patient-centered clinical studies and to ensure equitable access to evidence-based and state-of-the-art care as well as the ability to participate in research for all patients affected by breast cancer and other malignancies.

Twitter: @JuliaFoldiMD